Guided Therapeutics (GTHP) Change in Receivables (2011 - 2025)
Guided Therapeutics (GTHP) reported Change in Receivables of $8000.0 for Q2 2025, up 366.67% on a YoY basis from $1714.3 in Q2 2024, and up 900.0% sequentially from -$1000.0 in Q1 2025.
Guided Therapeutics (GTHP) Change in Receivables (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Change in Receivables data on file, last reported at $8000.0 in Q2 2025.
- For the quarter ending Q2 2025, Change in Receivables rose 366.67% year-over-year to $8000.0; the trailing twelve-month figure through Dec 2025 stood at $7000.0 (up 216.67% YoY), and the FY2025 full-year result was $7000.0, up 216.67% from the prior year.
- Change in Receivables grew to $8000.0 in Q2 2025, from -$1000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $22000.0 in Q4 2021 to a low of -$32000.0 in Q3 2022.
- A 5-year average of $769.23 and a median of -$1000.0 in 2023 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 600.0% in 2022, while the deepest fall reached 1700.0% in 2022.
- Tracing GTHP's Change in Receivables over 5 years: stood at $22000.0 in 2021, then sank by 245.45% to -$32000.0 in 2022, then soared by 112.5% to $4000.0 in 2023, then tumbled by 150.0% to -$2000.0 in 2024, then soared by 500.0% to $8000.0 in 2025.
- Business Quant data shows GTHP's Change in Receivables at $8000.0 in Q2 2025, -$1000.0 in Q1 2025, and -$2000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 42.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -444.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 287.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 117.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 117.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -124.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -141.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Sep 30, 2022 | -32,000.00 |
| Sep 30, 2022 | -32,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Mar 31, 2022 | 6,000.00 |